EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis

Yoshiya Tanaka, Nobuko Horiuchi, Cosmo Sasajima, Rumiko Matsumoto, Masafumi Kawanishi, Saeko Uchida, Tsutomu Takeuchi

Rheumatology and Therapy · 2025-04 · 12 (2) · 283-296

DOI: 10.1007/s40744-024-00737-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 27.01.2025. Verfasst von Yoshiya Tanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Kitakyushu, Fukuoka, 807-8555, …. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taisho Toyama Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX. METHODS: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching. Subsequently, the American College of Rheumatology (ACR) 20/50/70 response rates from baseline to 24 or 52 weeks were compared. Furthermore, to compare longitudinal data on disease activity indicators, a mixed-effects model for repeated-measures analyses was used. RESULTS: Comparing the OZR and MTX groups, 52 patients were matched in each group. The OZR group showed improvements in the ACR20 (OZR group, 67.3% vs. MTX group, 34.6%, p = 0.001), ACR50 (51.9% vs. 17.3%, p < 0.001), and ACR70 (26.9% vs. 11.5%, p = 0.047) response rates compared to those in the MTX group. Comparing the OZR and OZR + MTX groups, 77 patients were matched in each group. No significant difference was observed in the ACR20 response rate (OZR group, 58.4% vs. OZR + MTX group, 70.1%, p = 0.130). However, the OZR + MTX group showed higher ACR50 (44.2% vs. 62.3%, p = 0.024) and ACR70 (29.9% vs. 45.5%, p = 0.046) response rates. CONCLUSION: OZR administration without MTX was associated with an improvement in the signs and symptoms of RA compared to placebo administration (continuation of MTX monotherapy). OZR and MTX administration showed better efficacy than OZR administration alone.

Schlagwörter

Stichwörter der Autor:innen

Antitumor necrosis factor inhibitorCombination with methotrexateOzoralizumabPropensity score matchingRheumatoid arthritis

Autor:innen und Institutionen

  • The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Kitakyushu, Fukuoka, 807-8555, Japan. tanaka@med.uoeh-u.ac.jp.
  • Taisho Pharmaceutical Co., Ltd., 3-24-1, Takada, Toshima-ku, Tokyo, 170-8633, Japan.
  • Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
  • Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Förderung

  • Taisho Toyama Pharmaceutical Company

Zitieren

APA

Tanaka, Y., Horiuchi, N., Sasajima, C., Matsumoto, R., Kawanishi, M., Uchida, S., & Takeuchi, T. (2025). Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis. Rheumatology and Therapy, 12(2), 283-296. https://doi.org/10.1007/s40744-024-00737-3

Vancouver

Tanaka Y, Horiuchi N, Sasajima C, Matsumoto R, Kawanishi M, Uchida S, et al. Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis. Rheumatology and Therapy. 2025;12(2):283-296. doi:10.1007/s40744-024-00737-3

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Yoshiya and Horiuchi, Nobuko and Sasajima, Cosmo and Matsumoto, Rumiko and Kawanishi, Masafumi and Uchida, Saeko and Takeuchi, Tsutomu},
  title = {Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis},
  journal = {Rheumatology and Therapy},
  year = {2025},
  volume = {12},
  number = {2},
  pages = {283--296},
  doi = {10.1007/s40744-024-00737-3}
}
Kostenlos starten →